EU approves Yuflyma for multiple chronic inflammatory diseases – Celltrion Healthcare
Celltrion Healthcare announced that on February 11th, the European Commission (EC) has granted marketing authorisation for Yuflyma (CT-P17), an adalimumab biosimilar, across all thirteen intended indications for the… read more.
